Biostar Pharmaceuticals, Inc. reported unaudited consolidated earnings results for third quarter and nine months ended September 30, 2015. For the quarter, the company's sales, net were $4.206 million against $14.651 million a year ago. Loss from operations was $1.701 million against income from operations of $0.183 million a year ago. Loss before income tax was $1.244 million against income before income tax of $0.486 million a year ago. Net loss was $1.254 million or $0.08 per basic and diluted share against net income of $0.239 million or $0.02 per basic and diluted share a year ago.

For the nine months, the company's sales, net were $25.291 million against $47.031 million a year ago. Loss from operations was $3.664 million against $0.124 million a year ago. Loss before income tax was $2.545 million against income before income tax of $2.271 million a year ago. Net loss was $1.907 million or $0.12 per basic and diluted share against net income of $2.191 million or $0.15 per basic and diluted share a year ago. Net cash used in operating activities was $0.206 million against $0.544 million a year ago. Purchase of property, plant and equipment was $30,522 against $484,778 a year ago.